We hypothesize that GR antagonism will enhance chemotherapy sensitivity of GR+/ER− breast cancer cells by blocking stress-mediated cell survival pathways that would otherwise counteract chemotherapy-induced apoptosis in tumor cells. The gene discussed is NR3C1; the disease is breast carcinoma.